Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pumosetrag. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 2/20 | 0.98 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.48 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.48 |
| ▸ | HTR3D known ✓ | Q70Z44 | 1/20 | 0.48 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pumosetrag SCHEMBL29406201 | 1.00 | HTR3A (0.98) | HTR3ACYP3A4CHRNA7HTR3EHTR3B | |
| Pumosetrag SCHEMBL1497908 | 1.00 | HTR3A (0.98) | HTR3ACYP3A4CHRNA7HTR3EHTR3B | |
| Pumosetrag SCHEMBL390615 | 0.99 | HTR3A (1.00) | HTR3ACYP3A4CHRNA7HTR3EHTR3B | |
| Pumosetrag SCHEMBL1299656 | 0.99 | HTR3A (1.00) | HTR3ACYP3A4CHRNA7HTR3EHTR3B | |
| Pumosetrag SCHEMBL1299660 | 0.99 | HTR3A (1.00) | HTR3ACYP3A4CHRNA7HTR3EHTR3B | |
| Pumosetrag SCHEMBL1299759 | 0.97 | HTR3A (0.96) | HTR3ACYP3A4CHRNA7HTR3EHTR3B | |
| SCHEMBL1497938 | 0.95 | HTR3A (0.92) | HTR3ACYP3A4CHRNA7HTR3EHTR3B | |
| SCHEMBL1497911 | 0.91 | HTR3A (0.86) | HTR3ACYP3A4CHRNA7HTR3EHTR3B | |
| SCHEMBL1497977 | 0.83 | HTR3A (0.72) | HTR3ACYP3A4CHRNA7HTR3EHTR3B | |
| SCHEMBL1497721 | 0.77 | HTR3A (0.63) | HTR3ACYP3A4CHRNA7HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1256581-B1 | PREVENTIVE OR THERAPEUTIC AGENTS FOR GASTRIC OR ESOPHAGEAL REGURGITATION | MITSUBISHI PHARMA CORP (JP) | 2007-03-28 | — | — | EP | claimed |
| US-20050282852-A1 | Preventive and therapeutic medicament for gastroesophageal reflux disease | YAMAZAKI SATOSHI | 2005-12-22 | — | — | US | claimed |
| US-6967207-B2 | Preventive or therapeutic agents for gastric or esophageal regurgitation | MITSUBISHI PHARMA CORPORATION (JP) | 2005-11-22 | — | — | US | claimed |
| US-20040248927-A1 | Preventive agent/remedial agent for constipation predominant ibs | MITSUBISHI PHARMA CORPORATION (JP) | 2004-12-09 | — | — | US | claimed |
| US-20030130304-A1 | Preventive or therapeutic agents for gastric or esophageal regurgitation | MITSUBISHI PHARMA CORPORATION (JP) | 2003-07-10 | — | — | US | claimed |
| EP-1256581-A1 | PREVENTIVE OR THERAPEUTIC AGENTS FOR GASTRIC OR ESOPHAGEAL REGURGITATION | Mitsubishi Pharma Corporation (JP) | 2002-11-13 | — | — | EP | claimed |
| US-20230065814-A1 | CONJUGATES OF-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | ASCENDIS PHARMA A/S (DK) | 2023-03-02 | — | — | US | disclosed |
| US-20220305129-A1 | CONJUGATES OF HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | ASCENDIS PHARMA A/S (DK) | 2022-09-29 | — | — | US | disclosed |
| EP-3986472-A1 | CONJUGATES OF HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | Ascendis Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| EP-3986477-A1 | CONJUGATES OF pi-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | Ascendis Pharma A/S (DK) | 2022-04-27 | — | — | EP | disclosed |
| WO-2020254603-A1 | CONJUGATES OF π-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | ASCENDIS PHARMA A/S (DK) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020254606-A1 | CONJUGATES OF HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | ASCENDIS PHARMA A/S (DK) | 2020-12-24 | — | — | WO | disclosed |
| US-9533056-B2 | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs | ASCENDIS PHARMA AS (DK) | 2017-01-03 | — | — | US | disclosed |
| EP-1235565-B1 | USE OF 5HT 3 AGONISTS FOR RELAXING THE FUNDUS | JANSSEN PHARMACEUTICA NV (BE) | 2005-12-28 | — | — | EP | disclosed |
| US-20050209270-A1 | Use of 5HT3 agonists for relaxing the fundus | MEULEMANS ANN LOUISE G | 2005-09-22 | — | — | US | disclosed |
| US-20050119297-A1 | Use of 5HT3 agonists for relaxing the fundus | MEULEMANS ANN L G (BE) | 2005-06-02 | — | — | US | disclosed |
| US-20040248927-A1 | Preventive agent/remedial agent for constipation predominant ibs | MITSUBISHI PHARMA CORPORATION (JP) | 2004-12-09 | — | — | US | disclosed |
| EP-1419772-A1 | PREVENTIVE AGENT/REMEDIAL AGENT FOR CONSTIPATION PREDOMINANT IBS | Mitsubishi Pharma Corporation (JP) | 2004-05-19 | — | — | EP | disclosed |
| EP-1235565-A1 | USE OF 5HT 3 AGONISTS FOR RELAXING THE FUNDUS | Janssen Pharmaceutica N.V. (BE) | 2002-09-04 | — | — | EP | disclosed |
| WO-2001037824-A1 | USE OF 5HT3 AGONISTS FOR RELAXING THE FUNDUS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248927-A1 | Preventive agent/remedial agent for constipation predominant ibs | BRS3, SLC10A2, FABP2 | HTR3A 25/4885HTR3E 173/4885HTR3B 266/4885 |
| US-20050282852-A1 | Preventive and therapeutic medicament for gastroesophageal reflux disease | HRH2, SLC10A2, GRPR | HTR3A 798/4885HTR3E 975/4885HTR3B 1157/4885 |
| US-20220305129-A1 | CONJUGATES OF HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | NQO1, ABCB1, NCL | HTR3A 444/4885HTR3E 703/4885HTR3B 689/4885 |
| US-20230065814-A1 | CONJUGATES OF-ELECTRON-PAIR-DONATING HETEROAROMATIC NITROGEN-COMPRISING COMPOUNDS | NQO1, NCL, ABCB1 | HTR3A 677/4885HTR3E 1054/4885HTR3B 835/4885 |
| US-20030130304-A1 | Preventive or therapeutic agents for gastric or esophageal regurgitation | HRH2, SLC10A2, ABCB11 | HTR3A 2210/4885HTR3E 3051/4885HTR3B 3401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.